Get the Weekly Intelligence Brief — top committee picks every Sunday.
DVA · NYSE · STOCK

DaVita (DVA) Stock Analysis

Healthcare Updated August 25, 2026
$176.39
52W $101.00 – $247.49
53/100
$11.33B
15.2
0.87
AI Committee Verdict
Watch
53/100
Conviction: Contested · 50% agreement · 6 analysts
+1.8%
-17.7%
0.10:1
Contested

Is DVA Bullish or Bearish?

Mixed. Innellis AI committee rates DaVita (DVA) Watch with a composite score of 53/100 , based on 6 analysts with 50% agreement. Last updated August 25, 2026.

What Would Change This View

Upgrade to Buy
Requires a committee score of 60.0 — +6.68 from today. Applies on the first day at or above the line; upgrades are never dampened.
Downgrade to Reduce
Requires the score to fall below 40.0 — -13.32 from today. The band boundary is 45.0, but a one-step downgrade must clear a further margin first. A score oscillating around the line should not change the rating every night.

Executive Summary

The committee is genuinely divided. Growth Analyst sees a compelling case — 3 consecutive earnings beats -- consistent execution. Risk Analyst remains cautious — high leverage (debt-to-equity 77.99) amplifies downside in a stress scenario. This disagreement is itself the signal — the setup is not clean in either direction.

Bull & Bear Case

Bull Case
  • P/E of 13.6 is inexpensive for the broad market — Value
  • ROE of 181.2% shows genuine earnings power backing the valuation — Value
  • 3 consecutive earnings beats -- consistent execution — Growth
  • Quarter-over-quarter growth rate is ACCELERATING, not just positive — Growth
Bear Case
  • Price-to-book of 101.2x prices in significant intangible value — Value
  • Debt-to-equity of 77.99 adds balance-sheet risk to the value case — Value
  • RSI at 19 is in oversold territory (could mean either capitulation or a bounce setup) — Technical
  • MACD histogram negative -- bearish momentum — Technical
  • High leverage (debt-to-equity 77.99) amplifies downside in a stress scenario — Risk
  • Bollinger bandwidth of 56.4% signals elevated volatility — Risk
Both cases are generated from quantitative data signals, not qualitative or forward-looking judgement. They summarise what the numbers say today.
Price History (6M)

AI Investment Committee

Committee Consensus As of August 25, 2026
Overall Committee Score
53/100
Agreement
50%
Analysts
6
Conviction
Contested
Sector Rank
Top 77%
of 192 Healthcare peers
Value Analyst neutral
55 / 100 · High confidence
Fair value -- neither a bargain nor obviously overpriced
+ P/E of 13.6 is inexpensive for the broad market
− Price-to-book of 101.2x prices in significant intangible value
Growth Analyst bullish
68 / 100 · High confidence
Strong, accelerating growth with consistent execution
+ 3 consecutive earnings beats -- consistent execution
Technical Analyst bearish
38 / 100 · High confidence
Price action is deteriorating -- trend and/or momentum are working against this name
− RSI at 19 is in oversold territory (could mean either capitulation or a bounce setup)
Risk Analyst bearish
32 / 100 · Moderate confidence
Elevated risk from leverage, volatility, event exposure, or portfolio concentration -- size accordingly
− High leverage (debt-to-equity 77.99) amplifies downside in a stress scenario
Macro Analyst bullish
65 / 100 · Low confidence
Macro backdrop is supportive of risk assets generally, and this name's beta works in its favor
News Analyst bullish
61 / 100 · Low confidence
News flow and recent filings/analyst actions are net positive
Portfolio Manager neutral
45 / 100 · High confidence
Portfolio-level factors are mixed -- worth a deliberate sizing decision, not a default-size position
+ Portfolio position concentration is currently healthy
− Sector concentration is already high (HHI 3063.01)
Open Full Terminal →

Investment Thesis Evolution

Committee score moved marginally from 53.3 to 53.3.

Comparing 2026-08-24 to 2026-08-25 (1 day apart).

Technical Analysis

RSI (14)
28.1
Oversold
MACD Histogram
-1.427
Bearish Momentum
Trend Direction
Sideways
Weekly: Uptrend
Market Structure
Hh Hl
Support
$145.19
Resistance
$179.53
Bollinger %B
0.31
Inside Bands
Price vs Moving Averages
EMA 9
$179.70 Below
EMA 21
$192.55 Below
EMA 50
$201.53 Below
EMA 200
$175.27 Above

Fundamental Analysis

Valuation
95
Growth
84
Profitability
25
Financial Health
78
Cash Flow
70
Valuation
P/E Ratio 15.2×
P/B Ratio -14.94×
PEG Ratio 1.29
Dividend Yield 0.00%
52W High $247.49
52W Low $101.00
Quality & Growth
ROE -11470.2%
ROA 427.2%
Gross Margin 3102.4%
Operating Margin 1505.9%
Revenue Growth YoY
Debt / Equity -14.09
AI Fundamental Assessment
P/E ratio of 15.2 (inexpensive relative to a 15-40x range); Price-to-book of -14.9x; PEG ratio of 1.3 (under 1.0 suggests growth is undervalued relative to price); Return on equity of -114.7%; Return on assets of 4.3%; Net margin of 6.0%; Gross margin of 31.0%; Current ratio of 1.47 (tight short-term liquidity); Debt-to-equity of -14.09; Free cash flow per share is positive (24.85); Most recent quarter beat estimates by 2.5%; 3 consecutive earnings beats; EPS growth accelerating (-15.6% -> +40.1% QoQ); Average YoY EPS growth of 36.3%; Analyst estimates rising over recent quarters
Get the Full DVA Analysis
Interactive charts · Live committee votes · Trade plan · Paper trading · AI Q&A
Open in Terminal →
Weekly Intelligence Brief
Get the committee's top-scored stocks every Sunday.
Free · No spam · Unsubscribe anytime